Barclays PLC Boosts Holdings in Personalis, Inc. (NASDAQ:PSNL)

Barclays PLC increased its position in Personalis, Inc. (NASDAQ:PSNL) by 45.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,468 shares of the company’s stock after purchasing an additional 20,444 shares during the period. Barclays PLC’s holdings in Personalis were worth $352,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. nVerses Capital LLC purchased a new position in shares of Personalis in the third quarter worth $40,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in Personalis by 42.5% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock worth $81,000 after buying an additional 4,504 shares during the last quarter. International Assets Investment Management LLC lifted its stake in Personalis by 438.0% during the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock valued at $113,000 after acquiring an additional 17,082 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Personalis during the 3rd quarter valued at about $210,000. Finally, Semanteon Capital Management LP bought a new stake in shares of Personalis in the third quarter worth approximately $375,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. HC Wainwright increased their price objective on shares of Personalis from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Friday, December 20th. Needham & Company LLC reiterated a “buy” rating and set a $7.25 target price on shares of Personalis in a research note on Friday, December 20th.

Personalis Trading Up 5.9 %

PSNL opened at $6.64 on Friday. The company’s 50 day moving average is $4.64 and its 200 day moving average is $4.22. The company has a market cap of $469.10 million, a price-to-earnings ratio of -3.95 and a beta of 1.75. Personalis, Inc. has a 12-month low of $1.12 and a 12-month high of $7.20.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The business had revenue of $25.71 million for the quarter, compared to analysts’ expectations of $20.67 million. During the same quarter in the prior year, the business earned ($0.51) EPS. As a group, analysts predict that Personalis, Inc. will post -1.41 EPS for the current fiscal year.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.